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Abstract: Metastasis rarely occurs to the palatine tonsils. Herein, we present an exceedingly rare case of pala-
tine tonsillar metastasis from poorly differentiated lung adenocarcinoma with anaplastic lymphoma kinase (ALK) 
mutation in a 51-year-old woman. The patient manifested clinically as pharyngalgia without obvious respiratory 
symptoms, with swelling tonsil histomorphologically resembling lymphoma and partially expressing the markers 
of epithelial and squamous cell carcinoma (CK5/6, P63, and P40). Due to the non-specific immunohistochemical 
expression, it is easily misdiagnosed as a primary poorly differentiated squamous cell carcinoma of the tonsil. This 
case highlights the importance of a comprehensive assessment of suspicious tonsillar lesions, that may be a sign 
of a primary malignancy elsewhere in the body. 
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Case description
A 51-year-old female with symptoms of discom-
fort and pain in her throat for the duration of 20 
days, treated in our department, was examined 
to disclose a mass with ulcers and necrosis in 
the left palatine tonsillar fossa. A tissue biopsy 
showed atypical neoplastic cells that were dif-
fuse and densely distributed (Figure 1A). The 
cells were medium in size, single, and adherent 
to each other. The nucleus was round and 
medium-sized, with prominent nucleoli which 
were located in the center of the nucleus. Most 
cells were in mitosis, and no necrosis was 
observed in these cells. Immunohistochemical 
stains showed the neoplastic cells in the pala-
tine tonsil were positive for EMA, CD10 and 
pan-CK (Figure 1C), partially positive for p63, 
p40 and CK5/6 (Figure 1D), strongly positive 
for ALK P80 (Figure 1E), but negative for other 
B cell lymphoma correlation markers (CD20, 
CD3, CD4, CD8, CD5, CD30, PAX5, BCL2, BCL6, 
MUM1, C-MYC), malignant melanoma (S-100, 
HMB45) and follicular dendritic cell sarcoma 
(CD21, CD35). Synthesizing the characteristics 
of the partial expression of squamous epithelial 
carcinoma markers p63, p40 and CK5/6 by 
neoplastic cells and the high proliferation ki-67 
rate, the patient was diagnosed as poorly-dif-
ferentiated squamous cell carcinoma and 
geared up for tonsillectomy and cervical lymph-
adenectomy. In view of the strongly positive 
expression of ALK P80, we further ordered the 
pulmonary computed tomography (CT) exami-
nation. Enhanced CT scan revealed that a soft 
tissue mass in the lower lobe of the left lung 
was observed, the bronchi were truncated, the 
lesion’s border was less clearly surrounded by 
visible burrs, lower left lobe was slightly small-
er, and CT value was enhanced by enhance-
ment scanning. There were enlarged pulmonary 
hilum, neck and mediastinal lymph nodes, and 
a small arc liquid density shadow could be seen 
in the left chest. A positron emission tomogra-
Palatine tonsillar metastasis of lung adenocarcinoma
2289 Int J Clin Exp Pathol 2019;12(6):2288-2292
phy/computed tomography (PET/CT) scan 
detected abnormal cell metabolism, indicating 
primary tumor metastasized to the colon, liver, 
spleen and right lobe of thyroid. We also 
observed enlarged lymph nodes with increased 
cell metabolism in the left neck, double supra-
clavicular, mediastinum, double pulmonary 
hilum, and hepatic hilum. Thus, malignant le- 
sion metastasis was considered. Subsequently, 
the patient underwent an endobronchial ultra-
sound-guided transbronchial needle aspiration 
(EBUS-TBNA) showing histologic morphology 
similar to that of the tonsil (Figure 1B). As TTF1 
was positive in lung which always indicates a 
poorly differentiated adenocarcinoma, we fur-
ther performed the TTF1 immunohistochemis-
try of the tonsil tumor, and the result was dif-
fusely positive too which gave a sign of 
metastasis of lung cancer (Figure 1F). ARMS 
PCR was performed to detect EGFR, ALK and 
ROS1 genomic alteration profiles in lung cancer 
tissues. Interestingly, the ALK fusion gene 
Figure 1. A. The tonsil neoplastic cells had diffuse distribution with abundant cytoplasm and prominent nucleoli 
(Original magnification ×200, scale bar 300 µm). B. The histologic morphology of lung tumor tissue was similar to 
that of tonsil. (Original magnification ×200, scale bar 300 µm). C. Immunohistochemical results showed that tonsil 
neoplastic cells were positive for broad spectrum CK (Original magnification ×200, scale bar 300 µm). D. Few tonsil 
neoplastic cells were positive for CK5/6 (Original magnification ×200, scale bar 300 µm). E. ALK P80 was strongly 
positive in tonsil neoplastic cells (Original magnification ×200, scale bar 300 µm). F. TTF-1 was diffusely positive in 
tonsil neoplastic cells (Original magnification ×200, scale bar 300 µm).
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mutation was positive (Figure 2), while EGFR 
and ROS1 gene analysis revealed no 
mutations.
The patient was eventually diagnosed with a 
poorly differentiated adenocarcinoma of the 
lower lobe of the left lung with left tonsil and 
multiple organ metastases (T2N3M1, stageIV). 
She was transferred to the department of 
oncology and prescribed crizotinib for target- 
ed anti-tumor treatment, followed up closely. 
Unfortunately, the patient died of disseminated 
disease 5 months later after two cycles of 
chemotherapy. 
Discussion
Lung adenocarcinoma metastasizing to the 
tonsil is an extremely rare malignancy with a 
poor prognosis, and may be a pitfall for clini-
cians [1]. Although the pathway by which malig-
nancies metastasize to the tonsil remains con-
troversial and difficult to determine, hema- 
togenous spread, retrograde cervical lymphatic 
spread through the thoracic duct, or implanta-
tion metastasis during bronchoscopy [2] may 
be the potential mechanism. A metastatic 
tumor in an unusual site may make it trouble-
some to distinguish between a synchronous or 
metachronous primary cancer and a metastat-
mous markers’, even if diffuse, were entirely 
specific for squamous cell carcinoma. There- 
fore, a combination of multiple immunohisto-
chemical markers is helpful for the correct diag-
nosis of some atypical cases.
In addition, we noticed ALK P80 protein was 
positive immunohistochemically in our case. 
We also found EML4-ALK fusion gene mutation 
in lung adenocarcinoma. ALK oncogenic prop-
erties were initially identified in anaplastic large 
cell lymphoma (ALCL) accompanied by a unique 
reciprocal chromosomal translocation t (2;5) 
(p23;q35) in 1994 [7, 8]. This rearrangement 
yields a fusion gene called NPM-ALK thus re- 
sulting in the expression of an 80-kD oncogenic 
fusion protein designated ALK P80. Afterward, 
ALK was discovered to be rearranged, mutated, 
or amplified in such a series of tumors as dif-
fuse large B-cell lymphoma (DLBCL) [9], inflam-
matory myofibroblastic tumor (IMT) [10] and 
other diseases [11-16]. There is strong preclini-
cal evidence that ALK may be a driving force of 
oncogenesis in these cases. Lung adenocarci-
noma is a kind of malignant tumor with high 
heterogeneity in both histology and molecular 
genetics. As in our case, protein expression of 
ALK P80 was positive in EML4-ALK fusion lung 
adenocarcinoma. Although the predominant 
translocations such as NPM-ALK in ALCL and 
Figure 2. ARMS PCR showed ALK mutation in lung cancer tissue.
ic disease, especially when it 
is asymptomatic. In general, 
primary tonsil tumors are 
mostly squamous cell carci-
noma and lymphoma; other 
pathological types are rare. In 
the present case, the histo-
morphology changes of tonsil 
resembled lymphoma, while 
the histologic manifestations 
of palatine tonsil tumor cells 
showed a squamous epithelial 
phenotype that was positive 
for pan-CK, EMA, P63, P40 
and CK5/6. It is easily misdi-
agnosed as a primary poorly 
differentiated squamous cell 
carcinoma of the tonsil. Highly 
variable results have been 
reported over the years, par-
ticularly for the prevalence of 
‘squamous markers’ in adeno-
carcinoma [3-6]. As a single 
marker, only diffuse TTF-1 was 
specific for adenocarcinoma 
whereas none of the ‘squa-
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EML4-ALK in NSCLC are very characteristic for 
their respective tumor types, some ALK fusion 
proteins are occasionally shared by these histo-
logically diverse tumors. Currently, there is no 
research on whether there are oncogenes in 
the metastasis of lung cancer to the tonsils, 
and the correlation of tumorigenesis, metasta-
sis, and poor survival rate in ALK fusion gene 
and fusion protein is not clear, but deserves 
further study. 
As an important therapeutic target discovered 
in the field of lung cancer, ALK gene analysis 
should be routinely conducted at the same 
time as diagnosis for advanced NSCLC, adeno-
carcinoma, or other types of lung cancer with 
adenocarcinoma components. Patients with 
EML4-ALK fusion gene mutation generally have 
distinct clinical and pathological characteris-
tics, such as relatively young age of diagnosis 
(about 50 years old), no gender preference, 
non-smoking or light smoking, and are prone to 
early lymph node metastasis. Most of them are 
adenocarcinoma abundant in signet ring cells 
[17]. Both symptom remission rate and median 
progression-free survival can be significantly 
improved after ALK-TKI inhibitor administration 
[18]. In our case, the patient received crizotinib 
as targeted anti-tumor therapy. The initial effect 
was dramatic with lung tumor shrinkage. 
Unfortunately later she died of drug resistance, 
multiple metastases, and systemic diseases. 
Metastatic palatine tonsil cancer from a prima-
ry lung adenocarcinoma is an extremely rare 
malignancy with a poor prognosis. Metastasis 
in the palatine tonsil as the first symptom and 
having no obvious respiratory symptoms may 
be a pitfall for clinicians, and hence the 
advanced clinical stage of the disease is often 
found when first diagnosed. Comprehensive 
physical, immunohistochemical, and genetic 
examination can determine the source and 
nature of tumors, provide strong evidence for 
accurate diagnosis, treatment, and improve-
ment of prognosis. Individualized treatment 
strategies can be formulated according to 
patients’ pathologic types, molecular genetic 
characteristics, and physical states to maxi-
mize the survival time, control the disease pro-
gression and improve the quality of patients’ 
life.
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